Markus Hoffmann - I Tech Technical Director
| ITECH Stock | SEK 49.60 0.20 0.40% |
Insider
Markus Hoffmann is Technical Director of I Tech
| Phone | 46 10 30 33 999 |
| Web | https://www.i-tech.se |
I Tech Management Efficiency
The company has return on total asset (ROA) of 0.0201 % which means that it generated a profit of $0.0201 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0427 %, meaning that it generated $0.0427 on every $100 dollars invested by stockholders. I Tech's management efficiency ratios could be used to measure how well I Tech manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Anne Lanner | Hansa Biopharma AB | 54 | |
| Pr MD | Oncopeptides AB | N/A | |
| Linda Holmstrom | Oncopeptides AB | N/A | |
| MSc MSc | Oncopeptides AB | 53 | |
| Janus Larsen | Saniona AB | 51 | |
| Sren MSc | Hansa Biopharma AB | 58 | |
| Annika MBA | Oncopeptides AB | 57 | |
| Jakob Lic | Oncopeptides AB | 51 | |
| Anita BCom | Saniona AB | 55 | |
| Emanuel Bjrne | Hansa Biopharma AB | 50 | |
| MSc MD | Oncopeptides AB | N/A | |
| Klaus Sindahl | Hansa Biopharma AB | N/A | |
| Katja Margell | Hansa Biopharma AB | N/A | |
| MBA MSc | Saniona AB | 63 | |
| Rami Levin | Saniona AB | 54 | |
| Jorgen Drejer | Saniona AB | 68 | |
| Kristina Luthman | Oncopeptides AB | N/A | |
| Palle MS | Saniona AB | 65 | |
| Karin Nielsen | Saniona AB | N/A | |
| Peter Nygren | Oncopeptides AB | 64 | |
Management Performance
| Return On Equity | 0.0427 | |||
| Return On Asset | 0.0201 |
I Tech Leadership Team
Elected by the shareholders, the I Tech's board of directors comprises two types of representatives: I Tech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ITECH. The board's role is to monitor I Tech's management team and ensure that shareholders' interests are well served. I Tech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, I Tech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Philip Chaabane, Chief Officer | ||
| Cecilia Ohlauson, Head of Regulatory Affairs | ||
| Per Svensson, Sales Director | ||
| Markus Hoffmann, Technical Director | ||
| Magnus Henell, CFO Operations |
ITECH Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is I Tech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0427 | |||
| Return On Asset | 0.0201 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 662.35 M | |||
| Shares Outstanding | 11.91 M | |||
| Shares Owned By Insiders | 31.33 % | |||
| Shares Owned By Institutions | 37.93 % | |||
| Price To Book | 6.21 X | |||
| Price To Sales | 10.48 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for ITECH Stock Analysis
When running I Tech's price analysis, check to measure I Tech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy I Tech is operating at the current time. Most of I Tech's value examination focuses on studying past and present price action to predict the probability of I Tech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move I Tech's price. Additionally, you may evaluate how the addition of I Tech to your portfolios can decrease your overall portfolio volatility.